Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00687492

Purpose

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Condition
Hypercholesterolemia

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	8000
Study Start Date:	April 2008
Estimated Study Completion Date:	February 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Criteria

Inclusion Criteria:

2 or more risk factors (according to NCEP ATP III guideline)
Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
Previous enrolment or randomisation of treatment in the present study.
Participation in a clinical study during the last 90 days.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00687492

Contacts

Contact: Joy Leong

65-6330-1344

joy.leong@astrazeneca.com

Show 59 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

Park Jeong Euy

Sungkyunkwan University School of Medicine

More Information

Responsible Party:	AstraZeneca ( Joher Raniwalla )
Study ID Numbers:	NIS-CAP-DUM-2008/1
Study First Received:	May 28, 2008
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00687492
Health Authority:	Philippines: Bureau of Food and Drugs

Keywords provided by AstraZeneca:

hypercholesterolemia
NCEP ATP III guidelines
survey

Study placed in the following topic categories:

Metabolic Diseases
Hyperlipidemias
Metabolic disorder

Hypercholesterolemia
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009